SEC Comment Letter 0000000000-23-004103 to ARS Pharmaceuticals, Inc. (SPRY) (CIK 0001671858) (SPRY)

ARS Pharmaceuticals, Inc. (SPRY) (CIK 0001671858)
Date: April 24, 2023 · CIK: 0001671858 · Accession: 0000000000-23-004103

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-271359

Date

April 24, 2023

Author

Not clearly detected

Form

UPLOAD

Company

ARS Pharmaceuticals, Inc. (SPRY) (CIK 0001671858)

Letter

United States securities and exchange commission logo April 24, 2023 Richard Lowenthal, M.S., MSEL President and Chief Executive Officer ARS Pharmaceuticals, Inc. 11682 El Camino Real, Suite 120 San Diego, California 92130 Re:ARS Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed April 20, 2023 File No. 333-271359 Dear Richard Lowenthal: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Kenneth J. Rollins, Esq.

Show Raw Text

United States securities and exchange commission logo
April 24, 2023
Richard Lowenthal, M.S., MSEL
President and Chief Executive Officer
ARS Pharmaceuticals, Inc.
11682 El Camino Real, Suite 120
San Diego, California 92130
Re:ARS Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed April 20, 2023
File No. 333-271359
Dear Richard Lowenthal:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Kenneth J. Rollins, Esq.

SecProbe.io